Boston Scientific Reports Strong Q2 2025 Growth, Raises Full-Year Outlook

Boston Scientific Corporation has reported a robust financial performance for the second quarter of 2025, driven by significant growth across multiple medtech segments. The company has subsequently raised its financial forecasts for the remainder of the year, citing exceptional top-line performance and strategic investments in future growth.

Q2 Financial Highlights and Segment Performance

Boston Scientific logged a 22.8% increase in sales for Q2 2025 compared to the same period last year, pushing its total revenue to over $5 billion. This growth outpaced previous estimates of about 18.5%. The company's medical surgical tools division, including endoscopy, urology, and neuromodulation products, saw reported gains of 15.7%. The cardiovascular division demonstrated even stronger growth, with a 26.8% increase.

In the urology segment, Boston Scientific reported a 28.9% increase, driven by double-digit growth in its Rezum water vapor therapy for benign prostatic hyperplasia (BPH). The company's electrophysiology sales skyrocketed by 96.1% year-over-year, largely due to the continued commercial success of the Farapulse pulsed field ablation system for atrial fibrillation.

Key Product Developments and Regulatory Milestones

The Farapulse system, which received FDA approval in early 2024, generated $1 billion in revenue during its first 12 months on the market. In Q2 2025, it contributed $840 million to the company's cardiology segment, making it the largest single revenue generator in that division. The system recently received an additional FDA approval, expanding its reach to include patients with persistent atrial fibrillation lasting at least seven days.

Boston Scientific's Watchman franchise also saw significant growth, with a 28.4% increase driven by strong uptake in the U.S. market. The company reported success in pairing the Watchman left atrial appendage closure device with atrial fibrillation ablation in a single procedure aimed at reducing long-term stroke risks. Additionally, the latest version, Watchman FLX Pro, received CE mark approval in Europe during the quarter.

Strategic Acquisitions and Portfolio Management

The company finalized several strategic acquisitions during Q2, including the $540 million purchase of SoniVie, which brought an investigational renal denervation therapy for high blood pressure into Boston Scientific's portfolio. The company also completed its $175 million acquisition of Intera Oncology, adding a chemotherapy infusion pump for inoperable liver cancer to its product line.

In a significant portfolio management decision, Boston Scientific discontinued its Acurate family of transcatheter aortic valve replacements globally in late May. This move followed disappointing results in a U.S. clinical study and discussions with regulators. The company reported an impairment charge of approximately $130 million related to this restructuring.